They missed turning a profit in Q3 because of something like $9M-$10M in stock based compensation. I do expect a wider loss in Q1 based on "ramp up costs" - those 400 new reps and managers will be getting trained and learning their new territories, won't be make many sales at the start - I think JT may have even hinted about wider losses coming, might have been in relation to DTC advertising costs. Q4 is going to get hit hard by stock compensation too, assuming performance goals include gaining FDA approval, which would probably top the list of priorities.